Home › All Companies › CINGW › Annual Report

Cingulate Inc. (CINGW) — Annual Report

AI-Powered SEC Filing Analysis

← All CINGW filings
Latest Annual Report Filed: 2026-03-18

Key Insights

  • The company has experienced significant growth in its clinical operations, drug manufacturing, and personnel expenses over the past two years, indicating a focus on advancing its product pipeline.
  • Cingulate has entered into multiple financing agreements, including with Avondale Capital LLC and Streetville Capital LLC, which could provide additional capital to support its operations and development efforts.
  • The company has been actively issuing warrants and convertible securities to investors, which could lead to future dilution of existing shareholders if exercised.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-18. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Cingulate Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.